microdosing glp-1 for autoimmune conditions: what the research actually shows Chesapeake Express IV Wellness and

The global burden of cardiovascular diseases and risk: A compass for future health

Cost and insurance coverage are the biggest levers to GLP-1 adoption in Canada* Among Canadians with past/current/prospective GLP-1 interest (including alternative users), over half say that insurance coverage or a lower-cost generic would increase their likelihood of using a prescription GLP-1

If anxiety peaks when drug levels are highest, the dose may be too high

Parkinsons disease: pathogenesis and clinical aspects

These medicines are transforming obesity treatment and can achieve important weight loss

Overall, tirzepatides dual agonism of GLP1 and GIP receptors appears to provide encouraging cardiovascular benefits beyond glycemic control, offering a potential new therapeutic option for treating cardiovascular diseases and heart failure